Breast biopsy is a diagnostic procedure used involves the removal of sample from breast tissue for laboratory testing to determine the presence of cancerous cells. Biopsy is an initial test suggesting the area of tissue in the body not seems to be normal. There are different type of breast biopsy procedures performed in market which includes fine-needle aspiration, hollow or core needle and biopsy with vacuum-powered device. During breast biopsy, the test results are evaluated whether the suspicion area is cancerous or benign, and respective decision is taken regarding its treatment. Over the past few years screening and diagnostic market has improved and has eliminated the need for excisional biopsy to obtain a diagnosis of breast cancer.
Breast Biopsy Market: Drivers & Restraints
Approximately 12% women in the U.S. are likely to develop breast cancer during their lifetime. Factors contributing to rise in breast cancer cases is over consumption of alcoholic drinks, lack of physical exercise, improper diet and eating habits, high level of hormonal imbalance & exposure of skin to intense sunlight. However, limited awareness among female population and substandard healthcare facilities especially in developing regions are the factor restraining the growth of breast biopsy market.
Breast Biopsy Market: Segmentation
The breast biopsy market can be segmented on the basis of procedure type and end use.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1417
According to the procedure type, the breast biopsy market can be further segmented into:
- Fine needle aspiration biopsy
- Core needle Biopsy
- Stereotactic core needle biopsy
- Vacuum-assisted core biopsy
- Magnetic resonance imaging (MRI) guided biopsy
- Surgical biopsy
According to the End use, the breast biopsy market can be further segmented into:
- Cancer Research Organizations
- Diagnostic Laboratories
Breast Biopsy Market: Overview:
Mortality ratio of breast cancer is decreased since 1989 aided by early diagnosis and improved treatment. Diagnosis of breast cancer cannot be confirmed from mammograms and biopsy is mandatory. Risk of breast cancer increases with aging and thus is mostly observed in women over 50 years of age. Approximately about 77% women were diagnosed with breast cancer at the age of 50 and there are 2.8 million breast cancer survivor women living in the U.S. It is observed that there are various diagnostic companies investing into the research and development of new technique for breast imaging and needle biopsies.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1417
Breast Biopsy Market: Region-wise Outlook:
In the breast biopsy market, North America accounted for the largest market share due to the continuous development by companies operating into cancer diagnostics and growing demand for newer technique and treatments. Europe accounted for the second largest market share as breast cancer is most common in UK and Belgium and approximately 15% cases of breast cancer are diagnosed annually. Whereas the market share in Asia-Pacific region is likely to grow in subsequent years due to access to optimal treatment facilities and early detection.
Breast Biopsy Market: Key Players:
The major market players which operate into breast biopsy market include Becton, Dickinson and Company, Hologic, Inc., Leica Biosystems, Nussloch GmbH, C. R. Bard, Inc., Scion Medical Technologies, LLC, Planmed Oy and others.